In anticipation of potential approval of its MultiStem stem cell therapy, Cleveland biotechnology company Athersys Inc. is taking steps to be ready for possible commercialization.
Twenty-five years after it was founded in Cleveland, the company is actively preparing for what it expects to be successful results of multiple studies in the United States, as well as abroad in collaboration with its Japanese partner Healios K.K.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutre.
Originally published September 13, 2020.